11.00
U. Schmidt-Erfurth AUSTRIA
Neovascular AMD: AI evidence on novel grounds

11.06
S. Sivaprasad UK
Diabetic retinopathy severity: Diagnostic and therapeutic guidance

11.12
R. Tadayoni FRANCE
Surgery of (pseudo) holes: Standards in macular surgery

11.18
A. Loewenstein ISRAEL
Heads-up surgery: More options than ever

11.24
C.C.W. Klaver THE NETHERLANDS
The myopia pandemic: The European response

11.30
Discussion

11.45
End of session

12.00
A. Laidlaw UK
Realistic expectations in complex retinal detachment surgery

12.05
B. Corcóstegui SPAIN
Encirclement: what does it do? when to use it?

12.10
J. Garcia-Arumi SPAIN
PVR, when how and what to peel

12.15
T. Williamson UK
Retinectomy in PVR: early vs late

12.20
J.C. Pastor SPAIN
Risks with Tamponade agents

12.25
Discussion

12.45
End of session

14.00
E. Pilotto ITALY
Retinopathy in Type 1 diabetic children

14.06
A. Fawzi USA
Retinal blood flow in diabetic retinopathy

14.12
M. Paques FRANCE
Deferred laser in DME: follow ETDRS or aim for TelCaps?

14.18
N. Bressler USA
Current and future DRCRnet protocols in diabetic retinopathy

14.24
A. Laidlaw UK
Surgical solutions for DR, when to go in

14.30
Discussion

14.45
End of session

15.00
P. Keane UK
Artificial Intelligence in OCT and fundus images: Overview

15.07
T. Peto UK
Artificial Intelligence for DR screening

15.11
R. Tadayoni FRANCE
From DRSS to new imaging and AI

15.15
R. Sznitman SWITZERLAND
Biomarker detection in OCT scans

15.19
S. Sadda USA
Deep learning for assessment of AMD biomarkers

15.23
R. Schwartz UK
Using deep learning to detect reticular pseudodrusen on the UK Biobank – results and implications

15.27
Discussion

15.45
End of session

16.00
M. Berrocal PUERTO RICO
Rescue the View

16.01
Discussion

16.04
J. Garcia Arumi SPAIN
Lens Dislocation and Retinal Detachment in Marian Syndrome

16.05
Discussion

16.08
C. Claes BELGIUM
Oops, no way to make sclerotomies

16.09
Discussion

16.12
K. Kadonosono JAPAN
Limiting Phototoxicity During 3D Vitrectomy for Retinitis Pigmentosa

16.13
Discussion

16.16
X. Li CHINA
Air-Fluid Exchange…

16.17
Discussion

16.20
A. Maia BRAZIL
Retinal Detachment with Suprachoroidal Hemorrhage

16.21
Discussion

16.24
G. Pertile ITALY
Subretinal Injection of Membrane Blu Dual

16.25
Discussion

16.28
S. Priglinger GERMANY
Submacular Perfluoron

16.29
Discussion

16.32
S. Rizzo ITALY
Disposable Cryo

16.33
Discussion

16.36
D. Steel UK
Perfluoron Guided Subretinal TPA

16.37
Discussion

16.40
R. Tadayoni FRANCE
TBD

16.41
Discussion

16.45
End of session

08.30
C.C.W. Klaver THE NETHERLANDS
New insights from epidemiological studies

08.35
A. Tufail UK
Managing AMD patients: impact of AI-based biomarker detection in OCT scans

08.40
R. Guymer AUSTRALIA
Approaches to slow progression of intermediate AMD

08.45
Discussion

08.52
J. Mones SPAIN
Novel therapeutic approaches for neovascular AMD – better efficacy/longer duration?

08.57
C. Regillo USA
Long-acting drug delivery in nAMD: ARCHWAY phase 3 results

09.02
A. Loewenstein ISRAEL
Improving adherence and outcomes in AMD therapy: Home monitoring

09.07
Discussion

09.15
End of session

09.30
R. Schlingemann THE NETHERLANDS
New insights in the pathophysiology of diabetic macular edema in vein occlusion

09.36
P. Lanzetta ITALY
The management of macular edema in vein occlusion

09.42
J. Garcia-Arumi SPAIN
The surgical management of resistant cases of vein occlusion

09.48
F. Bandello ITALY
Is OCT-A essential in vein occlusion?

09.54
U. Schmidt-Erfurth AUSTRIA
Artificial intelligence in vascular retinal disease

10.00
Discussion

10.15
End of session

10.30
B. Bodaghi FRANCE
Viral retinitis

10.36
A. Adan SPAIN
New strategies with biologics in uveitis 

10.42
F. Pichi UNITED ARAB EMIRATES
OCTA in uveitis

10.48
J. van Meurs THE NETHERLANDS
Earlier antibiotic treatment is the most feasible step to improve treatment of endophthalmitis

10.54
J. Garcia-Arumi SPAIN
Surgical treatment of endophthalmitis

11.00
Discussion

11.15
End of session

13.45
C.C.W. Klaver THE NETHERLANDS
Myopia prevention

13.50
R. Finger GERMANY
AMD risk and progression

13.55
A. Schuster GERMANY
Glaucoma onset and progression

14.00
T. Peto UK
Diabetic eye diseases (DR & DME) onset, development of treatable stages, visual prognosis

14.05
C. Delcourt FRANCE
Diet and eye disease

14.10
Discussion

14.30
End of session

15.45
Impact of COVID on Retina Care: the aftermath

Panel
A. Tufail UK
A. Lowenstein ISRAEL
F. G. Holz GERMANY
S. Wolf SWITZERLAND
J. Garcia-Arumi SPAIN
C. Mariotti ITALY
L. Kodjikian FRANCE
J. Francois Korobelnik FRANCE

15.55
How does safe spacing/PPE affect the delivery of care – can we continue to be cost-effective?

Panel
R. Hamilton UK
S. Wolf SWITZERLAND
J. Garcia-Arumi SPAIN
J. Francois Korobelnik FRANCE

16.05
Should we alter our surgical environment?

Panel
R. Tadayoni FRANCE
A. Laidlaw UK
F. G. Holz GERMANY
J. Garcia-Arumi SPAIN
C. Mariotti ITALY

16.15
Is virtual the new reality? The Good, the Bad and the Ugly – Efficiency of virtual consults, conferences, and teaching

Panel
F. G. Holz GERMANY
A. Lowenstein ISRAEL
A. Tufail UK
R. Tadayoni FRANCE
E. Midena ITALY
S. Diehl Novartis
S. Leal Bayer

16.30
End of session

16.45
M. Michaelides UK
Phase 1/2 Clinical Trial of AAV-RPGR Gene Therapy for RPGR-Associated X-Linked Retinitis Pigmentosa: 9-month Results

16.50
F. G. Holz GERMANY
Zimura A Novel C5 Inhibitor, Significantly Reduces the Mean Rate of Geographic Atrophy Growth in the GATHER1 Clinical Trial

16.55
R. Tadayoni FRANCE
Oculis OCS-01 Phase 2 Study Results: A Topical Therapeutic for DME

17.00
R. Avery USA
RGX-314 Gene Therapy: Ongoing Phase I/IIa Interim Results

17.05
S. Sadda USA
Impact of pegcetocoplan on progression of nascent geographic atrophy in AMD

17.10
R. Tadayoni FRANCE
Investigating adverse events of intraocular inflammation with retinal vasculitis and/or retinal vascular occlusion in patients treated with brolucizumab

17.15
S. Khan UK
A Global Review of Publicly Available Datasets for Ophthalmic Imaging: Recognising Barriers to Access, Usability and Generalisability

17.20
G. Staurenghi ITALY, S. Charles USA, P. Keane UK
Innovation Discussions: 2020 News and Innovation in imaging, surgery, artificial intelligence

17.30
End of session

09.30
C. C.W. Klaver THE NETHERLANDS
Photoreceptor parameters as predictive biomarkers for geographic atrophy progression

09.37
J. Mones Spain
Lessons learned on AMD subtypes from the Eyerisk Study

09.51
C. Sanchez THE NETHERLANDS
From screen to bedside: how to implement AI in the management of retinal disease?

09.58
Discussion

10.15
End of session

10.30
K. Ohno-Matsui JAPAN
Ultra wide-field imaging of pathologic myopia

10.36
X. Li CHINA
Transmissions of OCT in PIC, PIC-CNV and M-CNV

10.42
L. Lu CHINA
Three years outcome of macular buckling for macularhole and foveoschisis in high myopic eyes

10.48
Y. Ikuno JAPAN
Surgical approach for myopic macular diseases

10.54
T. Ho TAIWAN
Thinking processes and practices in the management of vitreoretinal interface disorders in pathologic myopia

11.00
Discussion

11.15
End of session

10.45
D. Sarraf USA
PAMM VS AMN: Brothers in Arms or Strangers in the Night

10.51
S. Sadda USA
PEVAC

10.57
R. Schlingemann THE NETHERLANDS
Retinal vascular abnormalities associated with leakage and hard exudates, Telcaps and others

11.03
B. Leroy BELGIUM
Decision making in rare hereditary retinal disease

11.09
T. Wolfensberger SWITZERLAND
Surgical challenge-subject TBD

11.15
Discussion

11.30
End of session

12.30
C. Maschi FRANCE
Diagnosis and treatment of peripheral exudative haemorrhagic chorioretinopathy

12.35
H. Annas THE NETHERLANDS
Retinal Hemeangiomas – new insights in genetics

12.39
R. Hussain UK
Photodynamic therapy for the treatment of vasoproliferativhe tumours

12.43
Discussion

12.50
E. Midena ITALY
Challenges in radiation induced macula oedema

12.54
H. Heimann UK
Photodynamic therapy of choroidal melanoma

12.58
E. Kilic THE NETHERLANDS
Molecular genetics and clinical implications in uveal melanoma

13.02
TBC
Treatment of Metastatic Uveal Melanoma

13.07
Discussion

13.15
End of session